

VFC* Vaccine (regardless of state of residence)		
Vaccine	Ages Covered	Eligibility Criteria
DT [£]	6 weeks – 6 years	<ul style="list-style-type: none"> Only to be administered when DTaP is medically contraindicated. Call for approval prior to ordering.
DTaP	6 weeks – 6 years	
DTaP/HepB/IPV (Pediarix [®])	6 weeks – 6 years	<ul style="list-style-type: none"> Approved only for the primary series (i.e., 2, 4, and 6 months).
DTaP-IPV/Hib (Pentacel [®])	6 weeks – 4 years	<ul style="list-style-type: none"> Approved for use at 2, 4, 6, and 12 – 18 months of age.
DTaP-IPV	4 years – 6 years	<ul style="list-style-type: none"> Kinrix[®]: Approved for use as the fifth dose of DTaP and fourth dose of IPV at 4 – 6 years of age. Quadracel[™]: Approved for use as the fifth dose of DTaP and fourth or fifth dose of IPV at 4 – 6 years of age.
Hepatitis A	1 – 18 years	<ul style="list-style-type: none"> Should be routinely administered to children 12 – 23 months of age. Catch-up vaccination is recommended for all children ages 2 – 18 years.
Hepatitis B	Birth – 18 years	<ul style="list-style-type: none"> Hepatitis B birth dose at birthing hospitals. Approved for use at birth, 2, and 6 months of age.
Hib	6 weeks – 59 months	<ul style="list-style-type: none"> PedvaxHIB[®] is a three-dose series at 2, 4, and 12 – 15 months of age. (preferred for American Indian children) ActHib[®] is a four-dose series at 2, 4, 6, and 12 – 15 months. Hiberix[®] is a four-dose series at 2, 4, 6, and 12 – 15 months.
HPV9	9 years – 18 years	<ul style="list-style-type: none"> Gardasil[®] (HPV9) is available for both males and females ages 9 and older.
Influenza	6 months – 18 years	<ul style="list-style-type: none"> Influenza vaccine is recommended for everyone 6 months and older.
IPV	6 weeks – 18 years	
Meningococcal Conjugate (MCV4)	2 months – 18 years	<ul style="list-style-type: none"> Should be routinely administered to children 11– 12 years of age, with a booster dose at 16 years of age. Minimum age for Menactra[®] is 9 months. Minimum age for Menveo[®] is 2 months. Recommended for those at high risk of infection 2 months – 10 years of age.
Meningococcal B [£]	10 years – 18 years	<ul style="list-style-type: none"> Shared clinical decision making recommendation for administration to patients 16 – 18 years of age. Recommended for those at high risk of infection 10 – 18 years of age. Bexsero[®] (GlaxoSmithKline): two doses at least one

		<p>month apart.</p> <ul style="list-style-type: none"> • Trumenba® (Pfizer): two doses at 0 and 6 months. • Providers should have doses(s) on hand for high-risk VFC eligible patients or VFC patients who wish to be vaccinated.
MMR	12 months – 18 years	
MMRV	12 months – 12 years	<ul style="list-style-type: none"> • For the first dose of MMR and varicella vaccines at ages 12 – 47 months, either MMR and varicella vaccines administered separately or MMRV vaccine may be used. • For the second dose of MMR and varicella vaccines at any age (15 months – 12 years) and for the first dose at age ≥48 months, use of MMRV vaccine is generally preferred over separate injections.
Pneumococcal Conjugate (PCV13, Prevnar13®)	6 weeks – 59 months	<ul style="list-style-type: none"> • The ACIP recommends PCV13 for all children ages two through 59 months and for children ages 60 through 71 months who have underlying medical conditions that increase their risk of pneumococcal disease or complications. • Children 6 – 18 years of age with immunocompromising conditions such as HIV-infection, anatomic or functional asplenia, sickle cell disease, cochlear implant or cerebrospinal (CSF) leaks should also receive a dose of PCV13.
Pneumococcal Polysaccharide (PPSV23) [£]	2 – 18 years	<ul style="list-style-type: none"> • Available for high-risk children with one or more of the following conditions: <ul style="list-style-type: none"> ○ Chronic illnesses such as cardiovascular disease, chronic pulmonary disease, diabetes mellitus, alcoholism, chronic liver disease or CSF leaks. ○ Functional or anatomic asplenia (splenectomy) ○ Conditions associated with immunosuppression, including HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure, nephritic syndrome, or other conditions associated with immunosuppression (organ or bone marrow transplantation); and people receiving immunosuppressive chemotherapy, including long-term high-dose corticosteroids. ○ Cochlear implants. • Providers should have on hand for high-risk VFC eligible patients.
Rotavirus	6 weeks – 8 months, 0 days	<ul style="list-style-type: none"> • Rotateq® (Merck): three doses at 2, 4, and 6 months of age. • Rotarix® (GSK): two doses at 2 and 4 months of age.
Td [£]	7 – 18 years	<ul style="list-style-type: none"> • Tdap is recommended instead of Td for adolescents and adults. • Td or Tdap can be used in the following situations

		<p>where Td was previously recommended:</p> <ul style="list-style-type: none"> ○ Decennial booster dose ○ Tetanus prophylaxis for wound management ○ Catch-up immunization
Tdap	7 – 18 years	<ul style="list-style-type: none"> ● Tdap is recommended instead of Td for adolescents and adults.
Varicella (Chickenpox)	12 months – 18 years	
317 Vaccine (regardless of state of residence)		
Vaccine	Ages Covered	Eligibility Criteria
Any childhood vaccine listed in VFC section.	Birth – 18 years	<ul style="list-style-type: none"> ● Underinsured children seen at private provider offices.
Hepatitis B	Birth – 18 years	<ul style="list-style-type: none"> ● Hepatitis B birth dose available to insured infants at North Dakota birthing hospitals.
Adult Hepatitis A	19 years and older	<ul style="list-style-type: none"> ● Available for uninsured and underinsured adults. ● Not available for adults whose sole purpose for vaccination is international travel or employment. ● Persons at high risk for hepatitis A infection include: <ul style="list-style-type: none"> ○ Any drug user (injection or non-injection) ○ Have had tattoos or body piercings in unsterile environments ○ Have received blood clotting factors before 1987 ○ Have HIV or AIDS ○ Have had sex with an HIV-infected individual ○ Have undiagnosed liver problems ○ Have received donated blood or organs before 1992 ○ Are on long term hemodialysis ○ Have had sex with men who have sex with men (MSM) ○ Those experiencing homelessness or unstable housing
Adult Hepatitis B	19 years and older	<ul style="list-style-type: none"> ● Available for uninsured and underinsured adults. ● Not available for adults whose sole purpose for vaccination is international travel or employment. ● Persons at high risk for Hepatitis B infection include: <ul style="list-style-type: none"> ○ Any drug user (injection or non-injection) ○ Have had tattoos or body piercings in unsterile environments ○ Have received blood clotting factors before 1987 ○ Have HIV or AIDS ○ Have had sex with an HIV-infected individual ○ Have undiagnosed liver problems ○ Have received donated blood or organs before 1992 ○ Are on long term hemodialysis ○ Have had sex with men who have sex with men (MSM)

Adult Hep B/ Hep A (Twinrix®)	19 years and older	<ul style="list-style-type: none"> • Available for uninsured and underinsured adults. • Not available for adults whose sole purpose for vaccination is international travel or employment. • Persons at high risk for Hepatitis B infection include: <ul style="list-style-type: none"> ○ Any drug user (injection or non-injection) ○ Have had tattoos or body piercings in unsterile environments ○ Have received blood clotting factors before 1987 ○ Have HIV or AIDS ○ Have had sex with an HIV-infected individual ○ Have undiagnosed liver problems ○ Have received donated blood or organs before 1992 ○ Are on long term hemodialysis ○ Have had sex with men who have sex with men (MSM)
HPV9	19 – 26 years	<ul style="list-style-type: none"> • Available for uninsured and underinsured males and females. • Insured and Medicaid enrolled individuals must be vaccinated with private vaccine and insurance or Medicaid should be billed. • HPV9 vaccine is currently licensed for use in individuals up to the age of 45 years. Until insurance coverage for the upper age group is more universal, the 317 program coverage will remain the same and only cover individuals through 26 years of age.
Influenza	19 years and older	<ul style="list-style-type: none"> • Available for uninsured and underinsured adults at participating LPHUs and FQHCs.
Meningococcal Conjugate (MCV-4)	19 years – 55 years	<ul style="list-style-type: none"> • Available for uninsured and underinsured adults.
MMR	19 years and older	<ul style="list-style-type: none"> • Available for uninsured and underinsured adults.
PCV13	19 – 64 years	<ul style="list-style-type: none"> • Available for high risk uninsured and underinsured adults and meet one of the following criteria: <ul style="list-style-type: none"> ○ Immunocompromising conditions (e.g., congenital or acquired immunodeficiency, HIV, chronic renal failure, nephrotic syndrome, leukemia, lymphoma, Hodgkin disease, generalized malignancy, immunosuppression by corticosteroids or chemotherapy, solid organ transplant, and multiple myeloma) ○ Functional or anatomic asplenia (e.g., sickle cell disease and other hemoglobinopathies and congenital and acquired asplenia) ○ Cerebrospinal fluid (CSF) leak ○ Cochlear implant
PPSV23 [£]	19 – 64 years	<ul style="list-style-type: none"> • Available for high risk uninsured and underinsured adults and meet one of the following criteria: <ul style="list-style-type: none"> ○ cigarette smokers age 19 years and older ○ chronic cardiovascular disease (e.g., congestive heart failure, cardiomyopathies; excluding hypertension) ○ chronic pulmonary disease (including COPD and emphysema, and for adults ages 19 years and older, asthma) ○ diabetes mellitus

		<ul style="list-style-type: none"> ○ alcoholism ○ chronic liver disease, cirrhosis ○ candidate for or recipient of cochlear implant ○ CSF leak ○ functional or anatomic asplenia (e.g., sickle cell disease, splenectomy) ○ immunocompromising conditions (e.g., HIV infection, leukemia, congenital immunodeficiency, Hodgkin's disease, lymphoma, multiple myeloma, generalized malignancy) or on immunosuppressive therapy ○ solid organ transplantation; for bone marrow transplantation ○ chronic renal failure or nephrotic syndrome
Td/Tdap [£]	19 years and older	<ul style="list-style-type: none"> ● Available for uninsured and underinsured adults. ● A single dose is recommended for all adults, including those 65 years and older. ● Medicare Part D does cover Tdap, so therefore the adults who have Medicare Part D are considered insured and state-supplied vaccines cannot be used. Medicare Part B covers influenza and pneumococcal vaccines. ● If a patient does NOT have Medicare Part D and only has Medicare Part B (very rare), they would be considered underinsured and would qualify for state supplied Tdap.

All brands and presentations of vaccines listed on the vaccine coverage table are offered with regards to vaccine supply and availability according to the CDC and its distributors.

*VFC-eligible children are those who are 18 and younger and meet one of the following criteria:

- No health insurance
- Medicaid eligible
- American Indian or Alaskan Native
- Underinsured – have health insurance, but it does not cover a particular vaccine (**VFC vaccine can only be used for underinsured children at Rural Health Clinics, Federally Qualified Health Centers, and local public health units**)

NDIIS or Electronic Medical Record VFC Eligibility Data Entry:

- Children 18 and younger:
 - Medicaid
 - American Indian
 - Uninsured
 - Underinsured
 - Other State Eligible – insured children receiving hepatitis B birth dose
 - Not Eligible – all other insured children
- Adults
 - Other State Eligible – uninsured/underinsured adults receiving state-supplied HPV, Td/Tdap, MMR, MCV4, PCV13, PPSV23, influenza and adult hepatitis vaccines.
 - Not Eligible – all other adults

[£]PPSV23, Td and DT vaccines are all available for order in one dose increments.